Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014 (2014), Article ID 758283, 8 pages
http://dx.doi.org/10.1155/2014/758283
Research Article

Development of New Method for Simultaneous Analysis of Piracetam and Levetiracetam in Pharmaceuticals and Biological Fluids: Application in Stability Studies

1Faculty of Pharmacy, Federal Urdu University Arts, Science and Technology, Karachi 75300, Pakistan
2Faculty of Pharmacy, Ziauddin University, Karachi 75600, Pakistan
3Department of Chemistry, University of Karachi, Karachi 75270, Pakistan
4Department of Environmental Sciences, Federal Urdu University Arts, Science and Technology, Karachi 75300, Pakistan
5Faculty of Medicine, Ziauddin University, Karachi, Pakistan
6Department of Pharmacognosy, Research Institute of Pharmaceutical Sciences, Faculty of Pharmacy, University of Karachi, Karachi 75270, Pakistan

Received 5 February 2014; Accepted 4 June 2014; Published 8 July 2014

Academic Editor: Ali I. Abdalla

Copyright © 2014 Farhan Ahmed Siddiqui et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. The Merck Index, Merck & Co, Whitehouse Station, NJ, USA, 13th edition, 2001.
  2. S. Shorvon, “Pyrrolidone derivatives,” The Lancet, vol. 358, no. 9296, pp. 1885–1892, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. FDA Guidance for Industry, Stability Testing of DrugSubstances and Drug Products (Draft Guidance), Food and Drug Administration, Rockville, Md, USA, 1998.
  4. J. T. Carstensen and C. T. Rhodes, “A rational approach to stability testing and analytical development for NCE, drug products marketed product stability testing,” in Drug Stability: Principles and Practices, G. Wolfgang, Ed., pp. 415–481, Marcel Dekker, New York, NY, USA, 2000. View at Google Scholar
  5. O. A. Emmanuel, “Effect of packaging on stability of drugs and drug products,” in Pharmaceutical Manufacturing Handbook, C. D. Shayne and C. G. Shayne, Eds., pp. 641–686, John Wiley & Sons, Hoboken, NJ, USA, 2008. View at Google Scholar
  6. M. Contin, S. Mohamed, F. Albani, R. Riva, and A. Baruzzi, “Simple and validated HPLC-UV analysis of levetiracetam in deproteinized plasma of patients with epilepsy,” Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 873, no. 1, pp. 129–132, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. N. A. Raju, J. V. Rao, K. V. Prakash, K. Mukkanti, and K. Srinivasu, “Estimation of levetiracetam in tablet dosage form by RP-HPLC,” E-Journal of Chemistry, vol. 5, supplement 2, pp. 1098–1102, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Valarmathy, L. Samueljoshua, G. Rathinavel, C. S. Thanuja, and T. Sivakumar, “RP-HPLC method development andvalidation for assay of levetiracetam in tablet dosage form,” Research Journal of Pharmacy and Technology, vol. 1, no. 3, p. 395, 2008. View at Google Scholar
  9. J. M. Lobenhoffer and B. S. M. Boger, “Determination of levetiracetam in human plasma with minimal sample pretreatment,” Journal of Chromatography B, vol. 819, no. 1, pp. 197–200, 2005. View at Publisher · View at Google Scholar
  10. N. Ratnaraj, H. C. Doheny, and P. N. Patsalos, “A micromethod for the determination of the new antiepileptic drug levetiracetam (ucb LO59) in serum or plasma by high performance liquid chromatography,” Therapeutic Drug Monitoring, vol. 18, no. 2, pp. 154–157, 1996. View at Publisher · View at Google Scholar · View at Scopus
  11. T. A. C. Vermeij and P. M. Edelbroek, “High-performance liquid chromatographic and megabore gas-liquid chromatographic determination of levetiracetam (ucb L059) in human serum after solid-phase extraction,” Journal of Chromatography B: Biomedical Applications, vol. 662, no. 1, pp. 134–139, 1994. View at Publisher · View at Google Scholar · View at Scopus
  12. K. M. Matar, “Quantification of levetiracetam in human plasma by liquid chromatography-tandem mass spectrometry: application to therapeutic drug monitoring,” Journal of Pharmaceutical and Biomedical Analysis, vol. 48, no. 3, pp. 822–828, 2008. View at Publisher · View at Google Scholar
  13. G. Saravanan, G. Jyothi, Y. Suresh et al., “LC method for the determination of the stability of levetiracetam drug substance under stressing conditions,” Chromatographia, vol. 67, no. 1-2, pp. 173–177, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. M. S. Arayne, N. Sultana, F. A. Siddiqui, A. Z. Mirza, F. Qureshi, and M. H. Zuberi, “Simultaneous determination of piracetam and its four impurities by rp-hplc with uv detection,” Journal of Chromatographic Science, vol. 48, no. 7, pp. 589–594, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. J. F. Ovalles, J. N. A. Tettey, J. H. McB Miller, and G. G. Skellern, “Determination of piracetam and its impurities by TLC,” Journal of Pharmaceutical and Biomedical Analysis, vol. 23, no. 4, pp. 757–761, 2000. View at Publisher · View at Google Scholar · View at Scopus
  16. T. Guo, L. M. Oswald, D. R. Mendu, and S. J. Soldin, “Determination of levetiracetam in human plasma/serum/saliva by liquid chromatography-electrospray tandem mass spectrometry,” Clinica Chimica Acta, vol. 375, no. 1-2, pp. 115–118, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. M. H. Doheny, M. T. O'Connell, and P. N. Patsalos, “A high-performance liquid-chromatographic microanalytical procedure for the rapid estimation of piracetam in plasma or cerebrospinal fluid,” Journal of Pharmacy and Pharmacology, vol. 48, no. 5, pp. 514–516, 1996. View at Publisher · View at Google Scholar · View at Scopus
  18. H. Lamparczyk, P. Kowalski, D. Rajzer, and J. Nowakowska, “Determination of piracetam in human plasma by capillary electrophoresis,” Journal of Chromatography B: Biomedical Applications, vol. 692, no. 2, pp. 483–487, 1997. View at Publisher · View at Google Scholar · View at Scopus
  19. H. Bockhard, H. Oelschläger, and R. Pooth, “Fast detection of the nootropic drug piracetam in biological fluids,” Pharmazie, vol. 52, no. 5, pp. 357–361, 1997. View at Google Scholar · View at Scopus
  20. S. S. Boiko, V. P. Zherdev, T. A. Gudasheva et al., “The use of the HPLC method for the quantitative determination of a peptide analog of piracetam with nootropic activity and its main metabolites,” Eksperimental'naia i Klinicheskaia Farmakologiia, vol. 59, no. 2, pp. 38–40, 1996. View at Google Scholar · View at Scopus
  21. K. Louchahi, M. Tod, P. Bonnardel, and O. Petitjean, “Determination of piracetam in human plasma and urine by liquid chromatography,” Journal of Chromatography B: Biomedical Applications, vol. 663, no. 2, pp. 385–389, 1995. View at Publisher · View at Google Scholar · View at Scopus
  22. R. M. Nalbandian, M. F. Kubicek, W. J. O'Brien et al., “Liquid-chromatographic quantification of piracetam,” Clinical Chemistry, vol. 29, no. 4, pp. 664–666, 1983. View at Google Scholar · View at Scopus
  23. H. H. Yeh, Y. H. Yang, J. Y. Ko, and S. H. Chen, “Rapid determination of piracetam in human plasma and cerebrospinal fluid by micellar electrokinetic chromatography with sample direct injection,” Journal of Chromatography A, vol. 1120, no. 1-2, pp. 27–34, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. I. Karamancheva and T. Staneva, “Determination of possible impurities in piracetam using FTIR spectroscopy,” Journal of Pharmaceutical and Biomedical Analysis, vol. 21, no. 6, pp. 1161–1169, 2000. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Curticapean and S. Imre, “New validated method for piracetam HPLC determination in human plasma,” Journal of Biochemical and Biophysical Methods, vol. 69, no. 3, pp. 273–281, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. G. Hadad, R. Abdel-Salam, and S. Emara, “Optimized and validated flow-injection spectrophotometric analysis of topiramate, piracetam and levetiracetam in pharmaceutical formulations,” Acta Pharmaceutica, vol. 61, no. 4, pp. 377–389, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. ICH Harmonised Tripartite Guideline, “Validation of analytical procedures: text and methodology Q2 (R1),” 2005.
  28. ICH, “Stability testing of new drug substances and products,” in Proceedings of the International Conference on Harmonization, Geneva, Switzerland, 2003.
  29. K. Barkat, M. Ahmad, M. U. Minhas, M. Z. Malik, and M. Sohail, “Development of a simple chromatographic method for the determination of piracetam in human plasma and its pharmacokinetic evaluation,” Drug Research, 2014. View at Publisher · View at Google Scholar
  30. B. Mohammadi, M. Majnooni, N. Afnanzade, R. Jalili, and G. Bahrami, “Simple and rapid ultra high performance liquid chromatographic (UHPLC) method for the determination of levetiracetam in human serum: application to a bioequivalence study,” African Journal of Pharmacy and Pharmacology, vol. 6, no. 27, pp. 2017–2022, 2012. View at Google Scholar